BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PSI-7977: Phase IIb started

Pharmasset began the open-label, U.S. Phase IIb ATOMIC trial to evaluate 400 mg oral PSI-7977 daily plus Pegasys pegylated interferon alfa-2a and Copegus ribavirin in about 300 previously untreated patients with chronic HCV genotype 1. Patients...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >